GlassScriptPhysician profile
Christopher H Decker
NPI 1679734933
$6,207.85
in general payments reported to CMS, 2019-2025
34 companies · $1,089 in 2025
The $1,089 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $699 · 2020: $410 · 2021: $1,175 · 2022: $1,185 · 2023: $802 · 2024: $848 · 2025: $1,089.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,739.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,739.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,561.40 | 2019-2025 | Linzess, Rinvoq, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,022.79 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Genzyme Corporation | $574.94 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $419.47 | 2019-2025 | Entyvio |
| Celgene Corporation | $282.38 | 2021-2024 | Zeposia |
| Boston Scientific Corporation | $258.55 | 2019-2025 | Watchman Flx, Resolution Clip, Resolution 360 Ultra Clip |
| Pfizer INC. | $232.23 | 2019-2025 | |
| Janssen Biotech, INC. | $222.79 | 2019-2025 | Tremfya, Simponi, Stelara |
| Gilead Sciences, INC. | $191.33 | 2021-2025 | |
| Qol Medical, LLC | $156.62 | 2022-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $140.64 | 2024-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $140.35 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $136.02 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $114.66 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $86.27 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $85.77 | 2021 | |
| Daiichi Sankyo INC. | $80.99 | 2020-2022 | |
| Ipsen Biopharmaceuticals, INC | $73.83 | 2024-2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $73.37 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $67.36 | 2020-2023 | |
| Ucb, INC. | $43.25 | 2019 | |
| Amgen INC. | $39.55 | 2025 | Uplizna |
| Lilly USA, LLC | $28.19 | 2023-2024 | Omvoh |
| Intra-Sana Laboratories | $22.61 | 2023 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Ferring Pharmaceuticals INC. | $19.06 | 2019 | |
| Braintree Laboratories, INC. | $18.90 | 2022 | |
| Conmed Corporation | $18.00 | 2025 | Conmed Hemostasis |
| Celltrion USA INC. | $16.87 | 2025 | Vegzelma |
| Amag Pharmaceuticals, INC. | $14.97 | 2022 | |
| Mallinckrodt Hospital Products INC. | $14.30 | 2021 | |
| Novo Nordisk INC | $13.48 | 2025 | Saxenda, Wegovy |
| Enterra Medical, INC. | $13.28 | 2022 | |
| Evoke Pharma, INC. | $11.95 | 2022 | |
| Medtronic, INC. | $11.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Decker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.